Respiratory syncytial virus DNA vaccine - Vical

Drug Profile

Respiratory syncytial virus DNA vaccine - Vical

Latest Information Update: 31 Oct 2002

Price : $50

At a glance

  • Originator Vical
  • Class Gene therapies; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 31 Oct 2002 Discontinued - Preclinical for Respiratory syncytial virus infections in USA (Injection)
  • 19 Dec 2001 Aventis Pasteur is no longer involved in the development of respiratory syncytial virus DNA vaccine
  • 27 Nov 2001 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top